Hypertension in Cancer Patients and Survivors: Epidemiology, Diagnosis, and Management

Jordana B. Cohen, MD, MSCE, Abdallah S. Geara, MD, Jonathan J. Hogan, MD, Raymond R. Townsend, MD

This article has been selected as the month’s JACC: CardioOncology CME/MOC/ECME activity, available online at http://www.accjournals-cme by selecting the JACC Journals CME/MOC/ECME tab.

Accreditation and Designation Statement

The American College of Cardiology Foundation (ACCF) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ACCF designates this Journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Hypertension in Cancer Patients and Survivors: Epidemiology, Diagnosis, and Management will be accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of External CME credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME) and the European Board for Accreditation in Cardiology (EBAC) have recognized each other’s accreditation systems as substantially equivalent. Apply for credit through the post-course evaluation. While offering the credits noted above, this program is not intended to provide extensive training or certification in the field.

Method of Participation and Receipt of CME/MOC/ECME Certificate

To obtain credit for JACC CME/MOC/ECME, you must:

1. Be an ACC member or JACC: CardioOncology subscriber.
2. Carefully read the CME/MOC/ECME-designated article available online and in this issue of the Journal.
3. Answer the post-test questions. A passing score of at least 70% must be achieved to obtain credit.
4. Complete a brief evaluation.
5. Claim your CME/MOC/ECME credit and receive your certificate electronically by following the instructions given at the conclusion of the activity.

CME/MOC/ECME Objective for This Article: Upon completion of this activity, the learner should be able to: 1) identify factors contributing to the elevated risk of hypertension among cancer patients and survivors; 2) discuss approaches to blood pressure monitoring in cancer patients and survivors; and 3) select appropriate agents for the management of hypertension in cancer patients and survivors taking into consideration cancer treatment-specific morbidities and target organ damage.

Author Disclosures: This work was funded by National Institutes of Medicine–National Heart, Lung, and Blood Institute grant K23-HL133843 to Dr. Cohen. Dr. Hogan has received salary support from Retrophin, Caliditas, Omeros, and Achillion. Dr. Hogan has been a consultant for Retrophin; has served on advisory boards for Retrophin, Zyversa, and GlaxoSmithKline; and has received author payment from Dynamed and author royalties from UpToDate.com. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Marie Denise Gerhard-Herman, MD, served as Guest Editor-in-Chief for this paper. Anju Nohria, MD, served as Guest Editor for this paper. Anju Nohria, MD, served as Guest Editor-in-Chief for this paper.

Medium of Participation: Online (article and quiz).

CME/MOC/ECME Term of Approval

Issue Date: December 2019
Expiration Date: November 30, 2020

From the Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; and the Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. This work was funded by National Institutes of Medicine–National Heart, Lung, and Blood Institute grant K23-HL133843 to Dr. Cohen. Dr. Hogan has received salary support from Retrophin, Caliditas, Omeros, and Achillion. Dr. Hogan has been a consultant for Retrophin; has served on advisory boards for Retrophin, Zyversa, and GlaxoSmithKline; and has received author payment from Dynamed and author royalties from UpToDate.com. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Marie Denise Gerhard-Herman, MD, served as Guest Editor for this paper. Anju Nohria, MD, served as Guest Editor-in-Chief for this paper.

Manuscript received August 1, 2019; revised manuscript received November 1, 2019, accepted November 4, 2019.

https://doi.org/10.1016/j.jaccao.2019.11.009

ISSN 2666-0873
Hypertension in Cancer Patients and Survivors
Epidemiology, Diagnosis, and Management

Jordana B. Cohen, MD, MSCE,a,b Abdallah S. Geara, MD,a Jonathan J. Hogan, MD,a Raymond R. Townsend, MDa

ABSTRACT
Cancer patients and survivors of cancer have a greater burden of cardiovascular disease compared with the general population. Much of the elevated cardiovascular risk in these individuals is likely attributable to hypertension, because individuals with cancer have a particularly high incidence of hypertension following cancer diagnosis. Treatment with chemotherapy is an independent risk factor for hypertension due to direct effects of many agents on endothelial function, sympathetic activity, and renin-angiotensin system activity, as well as nephrotoxicity. Diagnosis and management of hypertension in cancer patients requires accurate blood pressure measurement and consideration of potential confounding factors, such as adjuvant treatments and acute pain, that can temporarily elevate blood pressure readings. Home blood pressure monitoring can be a useful tool to facilitate longitudinal blood pressure monitoring for titration of antihypertensive medications. Selection of antihypertensive agents in cancer patients should account for treatment-specific morbidities and target organ damage. (J Am Coll Cardiol CardioOnc 2019;1:238–51) © 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Essential hypertension is a leading cause of cardiovascular and kidney morbidity and mortality in the United States. On the basis of data from the 2011 to 2014 National Health and Nutrition Examination Survey, 46% of adults in the United States have hypertension when defined as having a blood pressure of $\geq 130/80 \text{ mm Hg}$ or self-reported to be taking an antihypertensive agent, and 32% have hypertension using the older definition of $\geq 140/90 \text{ mm Hg}$ (1). Non-Hispanic black individuals have a higher prevalence of hypertension compared with Hispanic, non-Hispanic white, and Asian individuals. The vast majority of people in the United States will develop hypertension during their lifetime, with lifetime prevalence estimates of $>80\%$ for white and Asian individuals, and $>90\%$ for black and Hispanic individuals (2).

The prevalence of hypertension is greater in cancer patients and survivors of cancer compared with the general population (3). Accordingly, hypertension is the foremost modifiable risk factor of adverse cardiovascular outcomes among cancer patients (3). The relationship between hypertension, cancer, and cardiovascular risk is multidimensional (Central Illustration). Hypertension, chronic kidney disease, cardiovascular disease, and cancer have several common risk factors, including smoking, diabetes mellitus, and obesity (4,5). Several cancers and cancer-related treatments directly cause hypertension, or indirectly mediate the develop of hypertension through nephrotoxicity. Several factors related to cancer treatment can confound blood pressure measurements. It is important to carefully measure and closely monitor blood pressures in cancer patients due to their particularly high risk of developing new or worsening hypertension. Furthermore, selection of antihypertensive agents should account for cancer treatment-specific adverse effects and individual risk factors. The goal of this review is to provide an approach to the monitoring and management of hypertension in cancer patients and survivors, accounting for patient-specific risk factors for the development and worsening of hypertension.

EPIDEMIOLOGY AND ETIOLOGY OF HYPERTENSION IN CANCER PATIENTS AND SURVIVORS

BURDEN OF HYPERTENSION IN PATIENTS WITH CANCER. Limited data exist examining the prevalence of hypertension among patients with cancer before undergoing cancer treatment. Small studies have found a similar prevalence of hypertension in patients with solid and neuroendocrine tumors before sorafenib therapy compared with the general population (6,7). One exception is Wilms tumor in children, where hypertension is more prevalent than in the general population, and may be associated with poor prognosis and response to therapy (8).
Several cancer treatments are associated with the development or exacerbation of hypertension (Table 1). Hypertension is the most common severe adverse event in patients with cancer receiving chemotherapy (9). One retrospective study analyzed the incidence of new-onset hypertension in a population of 25,090 adults with solid malignancies in the United States, and found that approximately one-third developed hypertension during follow-up (10). Patients with renal cancer had the highest rates of moderate hypertension (i.e., 150 to 160/100 to 110 mm Hg), whereas patients with gastric and ovarian cancers had the highest rates of severe (i.e., 160 to 180/110 to 120 mm Hg) and crisis-level (i.e., ≥180/120 mm Hg) hypertension, respectively. The median time to first event of moderate hypertension was 96 days from the time of their initial diagnosis with cancer. Chemotherapy exposure was identified as an independent risk factor for the development of hypertension.

**HIGHLIGHTS**

- Cancer patients and survivors are at a high risk for hypertension.
- Hypertension likely contributes to the high burden of cardiovascular disease in cancer patients and survivors.
- Accurate in- and out-of-office blood pressure measurement is important in cancer patients and survivors.
- Target organ damage and treatment-specific morbidities should be considered when selecting antihypertensive agents in cancer patients.

**ABBREVIATIONS AND ACRONYMS**

CI = confidence interval  
VEGF = vascular endothelial growth factor

**BURDEN OF HYPERTENSION IN CANCER SURVIVORS.**  
Patients who have a history of cancer have a high prevalence of hypertension compared with the general population. The Childhood Cancer Survivor Study found that hypertension was more common in >10,000 adults who had survived childhood cancer versus >3,000 siblings, and that this difference persisted as both groups aged (prevalence of 40% vs. 25% at age 45 years) (3). Obesity is associated with a 4-fold increased risk of hypertension in childhood cancer survivors. Other potential risk factors include prior treatment with high-dose corticosteroids, cyclophosphamide, ifosfamide, cisplatin, or abdominal radiotherapy (4). The prevalence of hypertension in childhood cancer survivors increases sharply with age, exceeding 70% by age 50 years (11); this prevalence is substantially higher than the general population after accounting for age-, sex-, race/ethnicity-, and body mass index-specific population rates.

**HYPERTENSION DUE TO CANCER TREATMENT.**  
Antivascular endothelial growth factor therapy and tyrosine kinase inhibitors. Hypertension associated with anti-vascular endothelial growth factor (VEGF) therapy and tyrosine kinase inhibitors is well-described. Hypertension has been reported in over one-half of patients treated with anti-VEGF therapy (12,13). The mechanism of anti-VEGF therapy-related hypertension is due to disruption of vascular homeostasis related to normal VEGF activity. This inhibition of VEGF yields a reduction in nitric oxide production (14) and angiogenesis (15) that lead to increased vascular resistance. Anti-VEGF therapy can also lead to fluid retention due to impaired natriuresis (16), endothelin-1-mediated vasoconstriction (17), as well as systemic thrombotic microangiopathy (18), similar to what is seen in preeclampsia.

A recent meta-analysis (19) studied the risk of cardiovascular disease in tyrosine kinase inhibitors therapy versus standard chemotherapy, and included 71 randomized controlled trials comprising >29,000 patients. The relative risk of hypertension with tyrosine kinase inhibitor therapy was 3.78 (95% confidence interval [CI]: 3.15 to 4.54). Treatment with tyrosine kinase inhibitors was also associated with a higher risk of cardiac ischemia (relative risk 1.69, 95% CI: 1.12 to 2.57; in subgroup analyses, highest with sorafenib and in renal cancer) and left ventricular systolic dysfunction (relative risk 2.53, 95% CI: 1.79 to 3.57). Another systematic review and meta-analysis (20) of 77 studies of angiogenesis inhibitors determined that the odds ratio for hypertension was 5.28 (95% CI: 4.53 to 6.15) with angiogenesis inhibitors compared with routine care (number need to harm = 6), and the odds ratio for severe (≥160/100 mm Hg) hypertension was 5.59 (95% CI: 4.67 to 6.69) (number needed to harm = 17). The meta-analysis did not find risk differences in patients exposed to direct VEGF inhibitors compared with tyrosine kinase inhibitors.

**Alkylating agents.** Alkylating agents have been important antineoplastic agents for decades. In current practice, alkylating agents are almost always used in combination with other agents, leading to the challenge of attributing specific adverse events to a liable agent. There are preclinical and clinical data indicating that some alkylating agents cause vascular toxicity and nephrotoxicity, which can indirectly result in hypertension. However, the causal link

SEE PAGE 252
between alkylating agents and hypertension remains unclear.

Cyclophosphamide has been associated with multiple vascular complications such as veno-occlusive disease in the lung and liver after hematopoietic cell transplantation, thromboembolic disease, and myocardial ischemia (21–23). Preclinical evidence has demonstrated endothelial injury and abnormalities in the renin-angiotensin system in animals treated with cyclophosphamide (24). Therefore, there is biological plausibility for cyclophosphamide-associated hypertension due to vascular injury. However, cyclophosphamide has not been identified as an independent risk factor for hypertension in cancer survivors.

Busulfan is an alkylating agent used in combination with oral cyclophosphamide as a conditioning regimen before allogeneic hematopoietic cell transplantation. This regimen has been used as an alternative, myeloablative strategy to oral cyclophosphamide plus total body irradiation. Hypertension was noted in 25% to 36% of adults who received busulfan, and in 58% of pediatric patients (25). Additional vascular toxicity has not been described, and no specific mechanism of action has been proposed (26,27). Correspondingly, bendamustine was reported to cause hypertensive emergency in 4 of 162 patients (2.4%) in a randomized controlled trial compared with chlorambucil for patients with
**TABLE 1** Cancer Treatments Associated With the Development and Exacerbation of Hypertension

| Chemotherapeutic agents | Mechanism(s) of Blood Pressure Elevation |
|-------------------------|----------------------------------------|
| Anti-VEGF therapy and tyrosine kinase inhibitors | Increased vascular resistance |
|                         | Reduced nitric oxide production (14) |
|                         | Reduced angio genesis (15) |
|                         | Impaired natriuresis (16) |
|                         | Endothelin-1-mediated vasoconstriction (17) |
|                         | Thrombotic microangiopathy (18) |
| Alkylating and alkyl-like agents | |
| Cyclophosphamide | Vascular endothelial injury (24) |
| Ifosfamide | Nephrotoxicity (31,32) |
| Cisplatin | Nephrotoxicity (33) and vascular endothelial injury (34) |
| Vinblastine | Vascular endothelial injury (in vitro) (35) |
| Gemcitabine | Vascular endothelial injury (in vitro) (38) |
| Radiation | |
| Abdominal radiation | Renal artery stenosis (41) |
| Head and neck radiation | Baroreflex failure (42,43) |
| Adjuvant therapies | |
| Erythropoietin stimulating agents | Increased erythrocyte mass |
| Nonsteroidal anti-inflammatory drugs | Impaired natriuresis due to reduction in prostaglandin synthesis (45) |
| Corticosteroids | Sodium retention due to mineralocorticoid receptor stimulation (46) |
| Calcineurin inhibitors | Systemic and renal vasoconstriction (47) |

**VEGF** = vascular endothelial growth factor.

previously untreated chronic lymphocytic leukemia (28,29). However, several patients in this study also experienced hypotension with bendamustine administration (6 of 162; 3.7%).

Nephrotoxicity of certain alkylating and alkyl-like agents is a likely driver of hypertension. Ifosfamide is known to cause nephrotoxicity, particularly with high-dose therapy in children (30). Hypertension has also been reported in cancer survivors who were previously treated with ifosfamide; it remains unclear whether ifosfamide exposure is an independent risk factor for the development of hypertension, or if hypertension is entirely mediated by ifosfamide-associated nephrotoxicity (31,32). Similarly, cisplatin and other platinum-based compounds, which are alkyl-like agents, have also been associated with nephrotoxicity and hypertension. The etiology of hypertension in patients treated with these agents is thought to be due to underlying renal injury (33), though vascular endothelial damage may also play a role (34).

**Antimicrotubule agents.** Antimicrotubule agents affect mitosis by acting on tubulin to prevent microtubule polymerization. In vitro studies support an effect of vinblastine on endothelial cell gene expression, particularly genes involved in apoptosis, cytoskeletal structure, cell cycle, and protein destruction (35). Vinca alkaloids have been noted to cause hypertension (36). However, because they are typically used in combination with other chemotherapies, the independent contribution of vinca alkaloids to the development or exacerbation of hypertension is not clear.

**Antimetabolite therapy.** Gemcitabine has been associated with the development of hypertension in the setting of thrombotic microangiopathy (37), with some evidence of endothelial damage in preclinical models of rapidly dividing endothelial cells (38).

**Proteasome inhibitors.** The proteasome inhibitors bortezomib and carfilzomib are currently used mostly as anti-plasma cell therapies in multiple myeloma. They have been observed to cause cardiac toxicity, which has occurred most commonly in patients treated with carfilzomib (39). Severe hypertension (i.e., blood pressure ≥160/100 mm Hg) is rare with proteasome inhibitors, and it is difficult to determine the relative contribution of proteasome inhibitors to hypertension in these cases because they are almost always used in combination with other therapies such as alkylating agents and corticosteroids. Cases of proteasome inhibitor-associated thrombotic microangiopathy have been reported (40), but the pathophysiological mechanism is unclear.

**Radiation.** Abdominal radiation has resulted in hypertension due to renal artery stenosis in rare cases (41). Radiation to the head and neck has been associated with baroreflex failure (42,43), which can manifest as labile hypertension or hypertensive crisis.

**Adjuvant therapies.** Many patients with cancer receive adjuvant therapies that can cause or worsen hypertension. These include erythropoietin-stimulating agents (44), nonsteroidal anti-inflammatory drugs (45), and corticosteroids (46). Calcineurin inhibitors, which are often prescribed after hematopoietic cell transplantation to prevent or treat graft versus host disease, can incite or exacerbate existing hypertension (47).

**Radical nephrectomy for kidney cancer is also associated with the development of hypertension (48), with partial nephrectomy (i.e., nephron-sparing surgery) potentially attenuating this risk (49).**

**Hypertension due to cancer.** Paraneoplastic hypertension. Hypertension can be a paraneoplastic feature of hepatocellular carcinoma, renal cell carcinoma, carcinoid, and several other cancers. In hepatocellular carcinoma, paraneoplastic hypertension is due to an excessive production of either renin, angiotensinogen, or angiotensin I by the carcinoma.
cells (50,51). Paraneoplastic hypertension secondary to excessive catecholamine urinary secretion has been described in some case reports of carcinoid tumors (52).

Among individuals with renal cell carcinoma, the prevalence of hypertension exceeds 75%. Hypertension in renal cell carcinoma has multiple contributing etiologies, particularly loss of nephron mass post-nephrectomy and treatment with VEGF inhibitors and tyrosine-kinase inhibitors (53). Renal cell carcinoma cells can also secrete vasoactive peptides, notably endothelin-1, leading to paraneoplastic hypertension (54). Paraneoplastic hypertension occurs in approximately 2% of patients diagnosed with renal cell carcinoma (55). The presence of paraneoplastic syndrome in renal cell carcinoma is a sign of aggressive disease, with worse prognosis.

**Pheochromocytoma and paraganglioma.** Pheochromocytoma and paraganglioma are neuroendocrine tumors arising from chromaffin cells in the adrenal medulla in the case of pheochromocytoma, and in the extra-adrenal autonomic paranglia in the case of paraganglioma (56). Pheochromocytoma and paraganglioma are rare tumors, with an annual incidence of 0.8 per 100,000 person-years (57). Approximately 10% of these tumors are malignant. Hypertension in pheochromocytoma and paraganglioma is caused by catecholamine hypersecretion (norepinephrine, epinephrine, and dopamine), and can be associated with symptoms including headaches, palpitations, and diaphoresis. However, at the time of diagnosis with pheochromocytoma or paraganglioma, these adrenergic symptoms are only present in about one-half of patients. Dopamine hypersecretion, documented by high plasma and urinary levels of dihydroxyphenylalanine and dopamine, has been associated with a more aggressive course and worse prognosis (58). Treatment is surgical resection, adjuvant chemotherapy, and/or radiotherapy.

**Adrenocortical carcinoma.** Adrenocortical carcinoma is a very rare tumor, with an incidence of 0.5 to 2 cases per 1 million person-years (59). These carcinomas most commonly present with Cushing’s syndrome, with features resulting from hypersecretion of glucocorticoid and/or androgens. Presentation with hyperaldosteronism is uncommon, and has only been reported in a few case reports (60). In either case, patients are likely to have hypertension as part of their presenting symptoms. Treatment is surgical resection, mitotane, and adjuvant chemotherapy and/or radiotherapy.

**Relationship between target organ damage and hypertension in cancer patients.** Chronic kidney disease. The relationship between hypertension and chronic kidney disease is bidirectional. Hypertension can result in glomerulosclerosis and microangiopathy, resulting in chronic kidney disease (61). Alternatively, chronic kidney disease causes and exacerbates existing hypertension via several mechanisms, including impaired natriuresis, elevated renin-angiotensin system activity, heightened sympathetic activity, and vascular endothelial injury.

The relationship between chronic kidney disease and cancer is also bidirectional. Cancer survivors...
have higher rates of chronic kidney disease secondary to therapy-related toxicities including chemotherapy nephrotoxicity (ifosfamide, cisplatin, anti-VEGF), recurrent acute kidney injury, abdominal radiotherapy, loss of nephron mass following nephrectomy, and direct cancer nephrotoxicity due to paraproteins or cryoglobulins (33,62). Individuals with chronic kidney disease are at a high risk of developing several cancers, including urothelial cancer, skin cancer, and thyroid cancer (63,64). An illustrative example of the bidirectional relationship between chronic kidney disease and cancer is that of end-stage kidney disease and renal cell carcinoma. Individuals with end-stage kidney disease have a 100-fold increased risk of developing renal cell carcinoma compared with the general population, whereas loss of nephron mass following nephrectomy for renal cell carcinoma leads to chronic kidney disease (65).

The association between chronic kidney disease and cancer is well-studied in childhood cancer survivors. In this population, the reported prevalence of chronic kidney disease ranges between 2.4% and 32%; this highly variable prevalence is related to differences in follow-up duration, chemotherapeutic regimens, and the definition of chronic kidney disease across different studies (11,33). Wilms tumor has a cumulative incidence of end-stage kidney disease of 0.7% after 20 years of follow-up (4); this incidence increases to 4.0% at 3 years after diagnosis in patients with synchronous bilateral Wilms tumor, and 19.3% in those with metachronous bilateral Wilms’ tumor.

**Cardiovascular disease.** With the increase in cancer survivorship, late treatment-related complications, including cardiovascular disease, are the primary source of long-term morbidity and mortality in cancer survivors (66,67). Hypertension is a significant risk factor in cancer survivors for developing coronary artery disease, heart failure, valvular heart disease, and arrhythmias. Hypertension has also been found to be more prevalent (66% vs. 60%), and was an independent risk factor for cardiovascular events, among adult cancer survivors compared with control subjects in a large study of the Kaiser Permanente Southern California-SEER (Surveillance, Epidemiology, and End Results) cancer registry (68). Furthermore, hypertension increases the risk of cardiotoxicity due to chest radiotherapy and anthracycline (5). Data are lacking regarding whether treating hypertension reduces the risk of cardiovascular events in cancer survivors; nonetheless, hypertension is the leading potentially modifiable risk factor for cardiovascular disease in this patient population.

**DIAGNOSIS AND MONITORING OF HYPERTENSION IN CANCER PATIENTS AND SURVIVORS**

**IN-OFFICE BLOOD PRESSURE MEASUREMENT.** In the United States, the majority of blood pressure measurements for screening for hypertension and titration of antihypertensive therapy occur in the clinic setting. Clinic blood pressure measurement can be performed using a manual aneroid manometer with auscultation of Korotkoff sounds or using an automated blood pressure monitor. Most blood pressure measurements in the office are performed by a medical assistant or nurse. These measurements may occur in the setting of time constraints or inadequate training, frequently resulting in inaccurate measurements (69). Consistent in-office measurements of blood pressure, using the appropriate approach to minimize confounders, is strongly recommended (69,70). This includes having the patient rest for 3 to 5 min before blood pressure measurement, with the measurement performed in a quiet room in the seated position, with the legs flat on the floor, the back supported (an examination table is typically not ideal), the arm supported at the level of the heart, the correct cuff size against a bare arm, an empty bladder, and no caffeine or cigarette smoking within 30 min before the measurement (71). Particularly in cancer patients and survivors, it is also important to assess for the presence of temporarily interfering substances (e.g., nonsteroidal anti-inflammatory drugs, erythropoietin-stimulating agents, and high-dose corticosteroids) and acute pain as potential confounders of blood pressure measurement during any given clinic visit (see later in the text, the section Management of Hypertension in Cancer Patients and Survivors).

Individuals with an elevated clinic visit blood pressure reading should have at least 2 additional blood pressure measurements performed during that clinic visit, because blood pressure improves with successive measurements in many individuals, and treatment recommendations are based on the average of 3 office readings (1,70). Automated office blood pressure measurement is a useful tool for achieving multiple blood pressure readings in a single visit. Automated office blood pressure measurement refers to the use of a fully automated device that has the ability to perform multiple consecutive blood pressure measurements with a single activation. Blood pressure measured using automated office blood pressures should be performed in a quiet room with or without the presence of a provider (72); these
measurements more closely resemble research-quality and daytime ambulatory blood pressure readings than typical clinic blood pressures (73).

Understanding the high risk of vascular toxicity and thromboembolic disease with many chemotherapies and cancers, patients should be assessed for inter-arm differences in blood pressure at least 1 time during the course of cancer treatment and again following treatment. If there is a reproducible $\geq 10$ mm Hg difference in systolic or diastolic blood pressure between the arms, the arm with the higher blood pressure should be used for future measurements (70).

### OUT-OF-OFFICE BLOOD PRESSURE MEASUREMENT.

#### White coat hypertension and masked hypertension.

Out-of-office blood pressure measurement addresses many of the limitations of clinic blood pressure measurement (74). In particular, out-of-office blood pressure measurement facilitates identification of white coat hypertension (elevated office blood pressure with normal out-of-office blood pressure) and masked hypertension (normal office blood pressure with elevated out-of-office blood pressure). Untreated white coat hypertension is associated with an increased risk of transition to sustained hypertension and adverse cardiovascular outcomes, whereas treated white coat hypertension is not associated with increased risk (75). Both treated and untreated masked hypertension are associated with a similarly increased risk of adverse cardiovascular outcomes as sustained hypertension (76,77). Thus, ongoing out-of-office monitoring is recommended in individuals with both white coat and sustained hypertension. Current guidelines recommend out-of-office blood pressure measurement in individuals whose office blood pressure is $\geq 120/70$ mm Hg to screen for masked hypertension (1).

Evidence suggests that white coat hypertension and masked hypertension may be more common in individuals receiving cancer treatment compared with the general population (78,79). The increased prevalence of white coat hypertension is proposed to be due to heightened anxiety associated with a diagnosis of cancer and fears surrounding prognosis. The increased prevalence of masked hypertension is likely in part due to delayed adverse effects of cancer treatments.

#### Approach to out-of-office blood pressure monitoring.

In patients undergoing active cancer treatment, blood pressure elevations can occur within a few hours or days, or may take up to a year to be evident (80). Given the rise in blood pressure following initiation of some cancer therapies, it is useful to supplement office blood pressures with out-of-office blood pressure monitoring. Options for out-of-office blood pressure...
measurement include ambulatory blood pressure monitoring and home blood pressure monitoring, also referred to as self-measured blood pressure at home (Table 2). Ambulatory blood pressure monitoring provides fully automated measurements over a 24-h period, typically performed every 15 to 30 min during the day and every 30 to 60 min at night. Ambulatory blood pressure monitoring is the reference standard for blood pressure measurement due to a stronger association with cardiovascular outcomes than clinic blood pressure measurements (74). However, ambulatory blood pressure monitoring can be intrusive and is difficult for patients to perform repeatedly in close succession for monitoring of changes in blood pressure (81).

Home blood pressure monitoring typically requires a patient to use a semiautomated blood pressure monitor to perform 2 measurements twice daily for a minimum of 3 (ideally 5 to 7) consecutive days. Although home blood pressure monitoring is prone to some of the measurement inaccuracies of clinic blood pressure monitoring, these can be readily addressed with patient education on appropriate measurement technique (82). Home blood pressure monitoring is able to identify white coat hypertension and masked hypertension, and facilitates close blood pressure monitoring for titration of antihypertensive medications, (83) making it favorable for longitudinal blood pressure monitoring in cancer patients.

On the basis of recent guidelines, we recommend 24-h ambulatory blood pressure monitoring for initial evaluation in all patients with an office blood pressure $\geq 120/70$ mm Hg (1). Although ambulatory blood pressure monitoring provides the most accurate and prognostically useful assessment of blood pressure, it is typically not feasible to perform more frequently than every 6 to 12 months (81). Home blood pressure monitoring has greater reproducibility and tolerability than ambulatory blood pressure monitoring, and thus is preferable for more frequent monitoring and for titration of medications over prolonged periods of time (69,84). Thus, we recommend home, rather than ambulatory, blood pressure monitoring to monitor for sufficient blood pressure control in patients on antihypertensive therapy. On the basis of the pharmacokinetics of most antihypertensive medications, we typically recommend that patients start to monitor their blood pressures at home for a minimum of 3 (ideally 5 to 7) days beginning 7 days after any changes to antihypertensive therapy, sooner if the individual is having severe or symptomatic hypertension. Specific cancer treatments may warrant more frequent monitoring, including anti-VEGF therapy, tyrosine kinase inhibitors, alkylating agents, and high-dose corticosteroids. Figure 1 presents an approach to out-of-office blood pressure monitoring in cancer patients and survivors, adapted from recommendations for home blood pressure monitoring in the general population to account for greater acuity in many patients on high-risk cancer therapy (70,82,85).
Selection of an automated blood pressure monitor. Most automated office and home devices use proprietary algorithms to estimate the systolic and diastolic blood pressure. It is important to select a clinically validated blood pressure monitor \((86,87)\). A listing of validated blood pressure devices available in the United States will be available in the near future from the American Heart Association and American Medical Association \((87)\). Current listings are also maintained by Hypertension Canada \((88)\), the British and Irish Hypertension Society \((89)\), and other international hypertension societies. Automated blood pressure monitors are prone to inaccuracies in certain clinical circumstances, such as arrhythmias and vascular disease. Given the elevated risk of these comorbidities in cancer patients and survivors, patient-specific validation of automated devices with a manual reading can be useful to ensure accuracy.

Due to the poor accuracy of most wrist, finger, and smartphone blood pressure devices \((90,91)\), upper arm devices are preferred. For individuals who have a contraindication to upper arm blood pressure measurement, such as those who have undergone bilateral lymph node dissection, there are currently 3 clinically validated wrist devices available in the United States (Omron BP4350, BP6100, and BP8000-M; Omron, Kyoto, Japan) \((92,93)\).

MANAGEMENT OF HYPERTENSION IN CANCER PATIENTS AND SURVIVORS

BLOOD PRESSURE THRESHOLDS TO INITIATE TREATMENT AND TREATMENT TARGETS. For normotensive patients with additional cardiovascular risk factors such as diabetes, elevated cholesterol, prior coronary heart disease, or active treatment with cardiotoxic chemotherapeutic agents who experience an increase in blood pressure, but whose blood pressure does not exceed a threshold level of \(\geq 130/80\) mm Hg or those with a blood pressure \(\geq 140/90\) mm Hg and are without additional cardiovascular risk \((1)\), lifestyle measures, especially sodium intake restriction, are a reasonable approach.

In previously normotensive patients who exceed the thresholds just described, or in hypertensive patients whose blood pressure becomes uncontrolled, adding therapy or titrating existing antihypertensive therapy is recommended. From a pragmatic standpoint, patients with active cancer have been excluded from standard hypertension trials in the past. Thus, there are little outcome data supporting antihypertensive therapy and blood pressure treatment thresholds. However, the increasing survival in cancer patients, and the cardiovascular toxicities of many cancer chemotherapeutic agents, predisposes these patients to cardiac death and future cardiovascular diseases \((66,67)\), making antihypertensive therapy a rational and useful consideration.

Recent trials support intensive blood pressure lowering in individuals at high risk of cardiovascular disease \((94-96)\); however, these studies did not include cancer patients. Whether the goal should be \(<130/80\) mm Hg in those at higher cardiovascular risk is unknown in this patient population.

SELECTION OF AGENTS FOR THE MANAGEMENT OF HYPERTENSION IN PATIENTS ON CANCER THERAPY.

Figure 2 presents an approach to therapy in the cancer patient whose blood pressure warrants drug treatment. Currently, no 1 class of antihypertensive drug is preferred. Because hypertension results from nephrotoxicity in several cancers and cancer treatments, our approach is to first assess for the presence of proteinuria. If proteinuria is present (spot albuminuria-to-creatinine ratio of \(\geq 300\) mg/g, or spot protein-to-creatinine ratio of \(\geq 500\) mg/g), drugs that block the renin-angiotensin system are reasonable agents to initiate or titrate \((1,97-99)\). Similarly, if left ventricular dysfunction is present, neurohormonal antagonists may be appropriate first-line drugs \((1,100)\). Moreover, limited retrospective data suggest that the use of renin-angiotensin system-blocking drugs may improve survival in cancer patients \((101)\).

Although there was initial concern that lowering blood pressure using medications such as angiotensin-converting enzyme inhibitors could, theoretically, offset the antitumor effect of VEGF inhibitors, this has not been observed in clinical practice, and antihypertensive therapy is recommended for these patients. In the absence of proteinuria, either a dihydropyridine calcium channel blocker or a renin-angiotensin system-blocking drug can be initiated. In our experience, the efficacy of calcium channel blockers such as amlodipine is reasonably high, particularly in African American patients \((102,103)\), and these drugs’ tendency to drug interactions and serious side effects are relatively low. Thus, we prefer adding, or titrating, amlodipine first when proteinuria is absent.

In individuals at high risk of volume depletion who also have proteinuria, it may be preferable to defer renin-angiotensin system-blocking drugs or, in those with transient risk of volume loss, recommend a sick-day protocol \((104)\) to temporarily withhold these medications on days in which they have symptoms. Correspondingly, diuretic and mineralocorticoid antagonist therapies are often added, or titrated, later in the cascade of antihypertensive therapy in patients.
on undergoing active cancer treatment, because these patients are at higher risk for volume depletion through reduced intake of nutrients and fluids, as well as increased volume losses from diarrhea or vomiting, predisposing them to electrolyte abnormalities and acute kidney injury. If there is no further individual-level contraindication, diuretic therapy (specifically thiazide and thiazide-like diuretics) should be considered first-line therapy in patients undergoing active surveillance and in cancer survivors (102). Similarly, if there is no contraindication, mineralocorticoid antagonist therapy should be used in individuals with resistant hypertension (105), with close monitoring for hyperkalemia.

Depending on the half-life and frequency of chemotherapy administration, some individuals may not be able to be treated with a fixed dose of antihypertensive medication. These individuals may particularly benefit from frequent home blood pressure monitoring (see the preceding section Approach to out-of-office blood pressure monitoring), including instructions on antihypertensive medication-holding parameters and appropriate supplemental dosing of antihypertensive medications for fluctuations in blood pressures related to chemotherapy administration and side effects.

**CONSIDERATION OF MEDICATION INTERACTIONS, INTERFERING SUBSTANCES, AND POLYPHARMACY.** Currently, non-dihydropyridine calcium channel blockers such as verapamil and diltiazem are avoided because they use cytochrome P450 3A4, a feature shared by many chemotherapy agents, risking potentiation of chemotherapy toxicity by inhibiting chemotherapy drug metabolism (80).

In some individuals undergoing active cancer treatment, the blood pressure cannot be controlled even with multiple antihypertensive agents. In this case, it is reasonable to discuss with the oncologist and the patient a trial of chemotherapy dose reduction, or a chemotherapeutic holiday period. It is also reasonable to consider dose reduction or temporary discontinuation of other therapeutic agents that may be contributing to high blood pressures, including nonsteroidal anti-inflammatory drugs, erythropoietin-stimulating agents, and high-dose corticosteroids.

Polypharmacy is common in cancer patients (106). In individuals who require >1 agent to achieve adequate blood pressure control, it is reasonable to use fixed-dose combinations of first-line agents to minimize pill burden and optimize adherence (107).

**APPROACH TO ELEVATED BLOOD PRESSURE IN THE SETTING OF PAIN AND ACCOUNTING FOR GOALS OF CARE.** The relationship between pain and blood pressure is complex, and the pathophysiology of this relationship seems to vary depending on the acuity of pain (108). Evidence suggests that greater intensity of chronic pain is associated with higher risk of hypertension (109). We recommend assessment of adequate pain control and titration of pain medications before initiating and up-titrating antihypertensive therapy in cancer patients. If chronic pain cannot be adequately controlled, there may be cardiovascular benefit to treatment with antihypertensive therapy to reduce blood pressure, especially if the blood pressure is persistently and/or severely elevated; however, there is a paucity of data to guide decision-making in this setting. In certain individuals and patient populations, it is reasonable to liberalize the treatment goal to <160/100 mm Hg (110). In this case, the risks and benefits of antihypertensive treatment should be discussed with the patient on the basis of their individual comorbidities, prognosis, and goals of care.

**SUMMARY AND CONCLUSIONS**

The burden of hypertension is particularly high in cancer patients and survivors, likely contributing to increased cardiovascular morbidity and mortality in these patients compared with the general population. There is a paucity of data on the benefit of blood pressure treatment in cancer patients with regard to cardiovascular risk reduction. Future studies are needed to identify optimal treatment targets and therapies for the management of hypertension in this patient population.

In the absence of high-quality evidence, individualized monitoring and treatment of hypertension in cancer patients and survivors is paramount. It is especially important to consider active cancer treatment, as well as the presence, intensity, and duration of adjuvant medications and pain when initiating and titrating antihypertensive medications. Proper blood pressure measurement technique and use of validated blood pressure devices is critical to obtaining accurate blood pressure measurements with which to make treatment decisions. Given improved survival among cancer patients in recent decades and the potential to reduce adverse long-term cardiovascular outcomes, it is important to engage cancer patients and survivors in the use of home blood pressure monitoring.

**ADDRESS FOR CORRESPONDENCE:** Dr. Jordana B. Cohen, Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, 423 Guardian Drive, 831 Blockley, Philadelphia, Pennsylvania 19104, USA. E-mail: jco@pennmedicine.upenn.edu. Twitter: @jordy_bc, @PennMedicine.
REFERENCES

1.Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/ABC/ACPM/AGS/APHA/ASH/ASCPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018;71:1217-248.

2.Carson AP, Howard G, Burke GL, Shea S, Levitan EB, Munterror P. Ethnic differences in hypertension incidence among middle-aged and older adults: the Multi-Ethnic Study of Atherosclerosis. Hypertension 2011;57:1101-7.

3.Armstrong GT, Geffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 2013;31:3673-80.

4.Kantar AF, Li FP, Janov AJ, Tarbell NJ, Maitland ML, Kasza KE, Karrison T, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009;15:6250-7.

5.Hill RJ Jr. Manufacturer’s labeling for paclitaxel. Cancer Invest 1996;14:644.

6.Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009;20:870-7.

7.Fraeman KH, Nordstrom BL, Luo W, Landis SH, Shahatak S. Incidence of new-onset hypertension in cancer patients: a retrospective cohort study. Int J Hypertens 2013;2013:379252.

8.Gibson TM, Li Z, Green DM, et al. Blood pressure status in adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study. Cancer Epidemiol Biomarkers Prev 2017;26:1705-13.

9.Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors. J Am Coll Cardiol 2015;66:1160-70.

10.Pinkhas D, Ho T, Smith S. Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development. Cardiooxidology 2017;3:5.

11.Hood JD, Meiningier CJ, Ziche M, Granger HJ. VEGF upregulates eNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998;274:H1054-8.

12.Madeddu P. Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp Physiol 2005;90:315-26.

13. Pandey AK, Singh HI, Arroyo JP, et al. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension 2018;71:e1-8.

14. Lankhorst S, Danser AH, van den Meiracker AH. Endothelin-1 and antiangiogenesis. Am J Physiol Regul Integr Comp Physiol 2016;310:R230-4.

15. Vigneau C, Lorange N, Dolly-Hitzé T, et al. All anti-vascular endothelial growth factor drugs can induce ‘pre-eclampsia-like syndrome’: a RARE study. Nephrol Dial Transplant 2014;29:325-32.

16. Totzeck M, Mincu RI, Mrotszek S, Schadendorf D, Rassaf T. Cardiovascular disease and cytomegalovirus infection. Am J Pathol 1980;99:369-86.

17. Abdel-Qadir H, Ethier JL, Lee DS. Thrombosis of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis. Cancer Treat Rev 2017;53:120-7.

18. Bruner WE, Pino J, Boitnott JK, Tutschka PJ, Santos GW. Pathology of the liver in patients with bone marrow transplantation. Effects of busulfan, carmustine, acute graft-versus-host disease, and cytomegalovirus infection. Am J Pathol 1980;99:369-86.

19. Talcott JA, Herman TS. Acute ischemic vascular events and cisplatin. Ann Intern Med 1987;107:121-2.

20. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991;9:1215-23.

21. Al-Hashmi S, Boels PJ, Jadidaji F, et al. Busulphan/cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase. PLoS One 2012;7:e30897.

22. Ben Venue Laboratories. Busulfex® (Busulfan Injection) [package insert]. Revised February 10, 1999. U.S. Food and Drug Administration website. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20954lbl.pdf. Accessed May 17, 2019.

23. Hartman AR, Williams SF, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplantation 1998;22:439-43.

24. Socie G, Ciff RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001;98:3569-74.

25. Knauf WU, Lissichkov T, Aldaoud A, et al. Treatment III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378-84.

26. Cephalon, Inc. TREANDA (bendamustine hydrochloride) [package insert]. Revised October 2008. U.S. Food and Drug Administration website. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022303lbl.pdf. Accessed July 15, 2019.

27. Skinner R, Cotterill SJ, Stevens MC, United Kingdom Children’s Cancer Study Group. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. Br J Cancer 2000;82:1636-45.

28. Mcmahon KR, Hare-Stirling M, Pizzi M, Huyhn L, Hessen E, Zappitelli M. Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study. Pediatr Nephrol 2018;33:2311-20.

29. Knijnenburg SL, Jaspers MW, van der Pal HJ, et al. Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors. Clin J Am Soc Nephrol 2012;7:1416-27.

30. Koojmans EC, Bokemampak A, Tjiajaji NS, et al. Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev 2019;3:CD008944.

31. Dursun B, Hez Z, Somerst H, Oh DJ, Faubel S, Eidelstein CL. Capsases and calpain are independent mediators of cisplatin-induced endothelial cell necrosis. Am J Physiol Renal Physiol 2006;291:F578-87.

32. Lucas CE, Gallagher H, Rochey V, Carroll WM, Gorelov A, Smith TJ. Global gene expression analysis of the effects of vinblastine on endothelial cells, when eluted from a thermo-responsive polymer. J Biomed Mater Res A 2006;79:246-53.

33. Stoter G, Koopman A, Vendrik CP, et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol 1989;7:1099-104.

34. Izzidene H, Isnard-Bagnis C, Launay-Vacher V, et al. Gemicatinib-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant 2006;21:3038-45.

35. van Hie AJ, Haimoiz-Friedman A, Fuku Z, Tap WD, Kolesnik R. Gemicatinib kills proliferating endothelial cells exclusively via acid sphingomyelinase activation. Cell Signal 2017;34:86-91.

36. Shah C, Bishnou R, Jain A, et al. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Leuk Lymphoma 2018;59:2557-69.

37. Kho JC, Van Keer J, Weiss BM, et al. Proteasome inhibitor associated thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant 2006;21:1023-7.
43. Sharabi Y, Dendi R, Holmes C, Goldstein DS. Baroreflex failure as a late sequela of neck irradiation. Hypertension 2003;42:110-6.
44. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012;12:CD003407.
45. Fournier JP, Sommet A, Bourrel R, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study. Eur J Clin Pharmacol 2012;68:1533-40.
46. Goodwin JE, Geller DS. Glucocorticoid-induced hypertension. Pediatr Nephrol 2012;27:1059-66.
47. Hoskova L, Malek I, Kopkan L, Kautzner J. Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension. Physiol Res 2017;66:167-80.
48. Nestler S, Levin P, Neisius A, et al. Incidence of cardiovascular events after nephrectomy: a single centre, matched pair analysis between donor and tumour nephrectomy in a long term follow-up. Urol Int 2016;97:142-7.
49. Capitainio U, Larcher A, Cianfalone F, et al. Hypertension as a paraneoplastic syndrome in hepatocellular carcinoma. J Gastroenterol 1999;34:530-4.
50. Kew MC, Leckie BJ, Grief MC. Arterial hypertension as a paraneoplastic phenomenon in hepatocellular carcinoma. Arch Intern Med 1989;149:2111-3.
51. van der Horst-Schippers AN, Wymenga AN, Linka TP, Willemse PH, Kema IP, de Vries EG. Complications of midgut carcinoid tumors and carcinoid syndrome. Neuroendocrinology 2004;80 Suppl 1:28-32.
52. Stojanovic M, Goldner B, Ilovic D. Renal cell carcinoma and arterial hypertension. Clin Exp Nephrol 2009;13:295-9.
53. Takahashi K, Totsune K, Kitamura T, Sone M, Murakami O, Shibahara S. Three vasoactive peptides, endothelin-1, adrenomedullin and urotensin-II, in human tumour cell lines of different origin: expression and effects on proliferation. Clin Sci (Lond) 2002;103 Suppl 48:355-85.
54. Moreira DM, Gershman B, Lohse CM, et al. Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy. World J Urol 2016;34:1465-72.
55. Lenders JW, Gershman B, Lohse CM, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:1915-42.
56. Beard CM, Shesg SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1983;58:802-4.
57. Hamidi O, Young WF Jr., Iniguez-Ariza NM, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab 2017;102:3296-305.
58. Luton JP, Cerda S, Billaud L, et al. Clinical features of adenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;322:1195-201.
59. Veron Esquivel D, Batiz F, Farias Vega A, Carrillo Gonzalez PA. Adrenocortical carcinoma, an unusual cause of secondary hypertension. BMJ Case Rep 2016;2016:bcr2016217918.
60. Townsend RR, Taler SJ. Management of hypertension in chronic kidney disease. Nat Rev Nephrol 2015;11:555-63.
61. Hogan J, Alexander MP, Leung N. Dyspepsia and the kidney: core curriculum 2019. Am J Kidney Dis 2019;74:822-36.
62. Lowance WT, Ordonez J, Udaltsova N, Russo P, Go AS. CKD and the risk of incident cancer. J Am Soc Nephrol 2014;25:2327-34.
63. Xu H, Matsuishi K, Su G, et al. Estimated glomerular filtration rate and the risk of cancer. Clin J Am Soc Nephrol 2019;14:530-9.
64. Denton MD, Magee CC, Ovuorie C, et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. Kidney Int 2002;61:2201-9.
65. Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2008;100:1368-79.
66. Agnion Nardi I, Iakovishilv Z. Cardiac risk in cancer survivors. Curr Treat Options Cardiovasc Med 2018;20:47.
67. Armstron NH, Xu L, Ky B, et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol 2016;34:1122-30.
68. Muntner P, Einhorn PT, Cushman WC, et al. Blood pressure assessment in adults in clinical practice and clinic-based research: JACC scientific expert panel. J Am Coll Cardiol 2019;73:317-35.
69. Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: a scientific statement from the American Heart Association. Hypertension 2019;73:635-66.
70. Kallioinen N, Hill A, Horswill MS, Ward HE, Watson MO. Sources of inaccuracy in the measurement of adult patients' resting blood pressure in clinical settings: a systematic review. J Hypertens 2017;35:421-41.
71. Johnson KC, Whelton PK, Cushman WC, et al. Blood pressure measurement in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension 2018;71:848-57.
72. Roeckele M, Kaczorowski J, Myers MG. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. JAMA Intern Med 2019;179:351-62.
73. Cohen JB, Cohen DL. Integrating out-of-office blood pressure in the diagnosis and management of hypertension. Curr Cardiol Rep 2016;18:112.
74. Cohen JB, Lotito MJ, Trivedi UK, Denker MG, Cohen DL, Townsend RR. Cardiovascular events and mortality in white coat hypertension: a systematic review and meta-analysis. Ann Intern Med 2019;170:853-62.
75. Pierdomenic SO, Pierdomeni AM, Cocima F, et al. Prognostic value of masked uncontrolled hypertension. Hypertension 2018;72:862-3.
76. Bangase JR, Rulope LM, De la Sierra A, et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med 2018;378:1509-20.
77. Costa LJ, Varella PC, Del Giglio A. White coat effect in breast cancer patients undergoing chemotherapy. Eur J Cancer Care (Engl) 2003;12:372-3.
78. Briasas A, Manios E, Karadimos A, et al. The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer. Eur J Cancer 2011;47:1660-8.
79. Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2768-801.
80. Kronish IM, Kent S, Moise N, et al. Barriers to conducting ambulatory and home blood pressure monitoring during hypertension screening in the United States. J Am Soc Hypertens 2017;11:573-80.
81. American Heart Association and American Medical Association. Tools & Downloads. . Revised July 25, 2019. Target.BP website. Available at: https://targetbp.org/tools-downloads/nort-topics/–Patient-Measured%20B. Accessed July 28, 2019.
82. McManus RJ, Mart J, Haque MS, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASSMIN-SR randomized clinical trial. JAMA 2014;312:799-808.
83. Piper MA, Evans CV, Burda BU, Margolis KL, O'Connor E, Whitlock EP. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2015;162:192-204.
84. Self-Measured Blood Pressure Monitoring. Actions Steps for Clinicians. Atlanta, GA. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, 2014.
85. Melville S, Byrd JB. Out-of-office blood pressure monitoring in 2018. JAMA 2018;320:1805-6.
86. Cohen JB, Padwal RS, Gutkin M, et al. History and justification of a national blood pressure measurement validated device listing. Hypertension 2019;73:258-64.
87. Blood Pressure Devices Recommended by Hypertension Canada. 2018. Available at: https://hypertension.ca/hypertension-and-you/managing-
hypertension/measuring-blood-pressure/devices/. Accessed June 20, 2018.

89. British and Irish Hypertension Society. BP Monitors. 2018. Available at: https://bihbsc.org/bp-monitors/. Accessed June 20, 2018.

90. Casiglia E, Tikhonoff V, Albertini F, Palatini P. Poor reliability of wrist blood pressure self-measurement at home: a population-based study. Hypertension 2016;68:896–903.

91. Plante TB, Urea B, MacFarlane ZT, et al. Validation of the instant blood pressure smartphone app. JAMA Intern Med 2016;176:700–91.

92. Kishore SP, Salam A, Rodgers A, Jaffe MG, Mitchell GD. Tyrosine kinase inhibitor-induced hypertension. Curr Oncol Rep 2018;20:65–6.

93. Wright JT Jr., Williamson JD, Whelton PK, et al., SPRI NT Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103–16.

94. Gushman WC, Evans GW, Byington RP, et al., ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575–85.

95. Agarwal M, Thareja N, Benjamini M, Akhondi A, Mitchell GD. Tyrosine kinase inhibitor-induced hypertension. Curr Oncol Rep 2018;20:65–6.

96. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1–150.

97. Faries CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA/HA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017;136:e137–61.

98. Li XY, Sun JF, Hu SQ. The renin-angiotensin system blockers as adjunctive therapy for cancer: a meta-analysis of survival outcome. Eur Rev Med Pharmacol Sci 2017;21:1375–83.

99. Wright JT Jr., Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorothalidone, amiodipine, and lisinopril. JAMA 2005;293:1595–608.

100. Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 ACC/AHA/ABC/APA/ACP/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018;71:2176–98.

101. Wright JT Jr., Williamson JD, Whelton PK, et al., SPRI NT Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103–16.

102. Wright JT Jr., Williamson JD, Whelton PK, et al., SPRI NT Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103–16.

103. Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the anti-hypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006;48:374–84.

104. Bruehl S, Chung OY, Jirjis JN, Birdeepalli S. Prevalence of clinical hypertension in patients with chronic pain compared to nonpain general medical patients. Clin J Pain 2005;21:147–53.

105. Mallory LH, Allen M, Fleming I, et al. Promoting higher blood pressure targets for frail older adults: a consensus guideline from Canada. Cleve Clin J Med 2014;81:427–37.

KEY WORDS blood pressure, cancer, cancer survivorship, hypertension, outcomes, pharmacotherapy, tyrosine kinase inhibitors

Go to http://www.acc.org/jacc-journals-cme to take the CME/MOC/ECME quiz for this article.